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A micromethod for the determination of ca'rbamazepine in small blood samples by high speed liquid chromatography is reported.
Carbamazepine is extracted into chloroform and determined by adsorption chromatography on Perisorb A. The minimal quantitatively
detectable concentration of carbamazepine is 0.5 mg/1, requiring 100 μ\ of plasma, the relative standard deviation at therapeutic plasma
levels being 3.8%.
Eine Mikromethode zur Bestimmung von Carbamazepin in kleinen Blutproben durch Fl ssigkeitschromatographie mit hohen Eingangs-
drucken wird beschrieben. Carbamazepin wird mit Chloroform extrahiert und mittels Adsorptionschromatographie auf Perisorb A
analysiert. Geht man von 100 μ\ Plasma aus, so betragen die minimal nachweisbare Carbamazepin-Konzentration 0,5 mg/1 und die relative
Standardabweichung 3,8% im therapeutischen Bereich.
Carbamazepine (5-H-dibenz [b, f] azepine-5-carboxa-
mide), an iminostilbene derivative, is widely used for
the treatment of · certain convulsive disorders and
trigeminal neuralgia. The drug has a marked anti-
convulsive and psychotropic activity in adults and
children (1—4). Investigations relating dose, serum
concentration, and therapeutic effects are useful in the
evaluation of the drug. Analytical methodology re-
ported for the determination of carbamazepine serum
concentrations includes the use of spectrophotometric
(5^ 6), thin layer (7, 8), and gas Chromatographie
methods (9—13). This paper describes a simple, rapid
and sensitive high speed liquid Chromatographie
estimation of carbamazepine, which requires only
100 μ\ of plasma.
Methods and Materials
Reagents
Carbamazepine was kindly donated by Ciba-Geigy AG (Basel),
the other chemicals were obtained from Merck AG (Darmstadt).
Carbamazepine standards were prepared by dilution of an ethanolic
stock solution with serum.
Apparatus
A Hewlett-Packard Hupe -f Busch series UFC 1000 high pressure
liquid Chromatograph with an UV absorbance detector (254 nm)
was used. The Chromatograph was equipped with a 2 χ 2000 mm
stainless steel column, handpacked by the tap-fill method (14)
with Perisorb A (Merck).
The mobile phase was /-octane/ethanol/water (volumes 85.7 1 +
14.0 1 + 0.31). The flow rate was 0.40 ml/min under a pressure
of 14 at. The columns were operated at ambient temperature.
Preparation of samples
50 μ\ of chloroform were added to 100 μ\ of plasma in -a 300 μ\
plastic centrifuge microtube. The mixture was shaken vigorously
for l min and centrifuged for l min at 15000^. Without further
separation steps 5 μ\ of the chloroform phase were injected into
the Chromatograph with a high pressure microsyringe (Scientific
Glass Engineering PTY) using the continuous flow technique. To
avoid any elution of UV absorbing tube materials into the chloro-
form layer, the whole procedure should be finished within 30 min.
Two synthetic sera containing 5 and 10 mg/1 carbamazepine were
prepared in the same way and injected at the beginning and the
end of each series. The peak areas were evaluated with a piano-
meter (Ott Kompensationspianometer Nr. 19).
Results and Discussion
Selection of column and solvent
Following a scheme publicated by SNYDER (15) different
stationary and mobile phases were examined for ade-
quate separation conditions. The Chromatographie
system selected for carbamazepine analysis, was obtained
by varying the relation of the solvent components
/-octane, ethanol, and water on columns packed with
irregular shaped silicagel beads of various sizes (Mercko-
sorb SI 60; 10, 20 and 30 μτη) and Perisorb A, a con-
trolled surface porosity Chromatographie support.
Figure 1 illustrates a chromatogramm of a patient's
plasma.
Precision
The coefficient of variation was 3.8% in 20 replicate
determinations of the same plasma containing 10 mg/1
carbamazepine and in 30 different duplicate plasma
analyses ranging from 0.8 to 5.5 mg/1 carbamazepine.
The use of an internal standard (benzidine) gave no
higher precision and was therefore of no advantage.
Plotting the concentration vs the peak area of car-
bamazepine standards produced a straight line over the
range of 0.5 to 50 mg/1. The calibration curve passed
through the origin. The minimal quantitatively detec-
table amount of carbamazepine was 2.5 ng correspond-
ing to 5 μ\ of a solution containing 0.5 mg/1.
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Carbamazepine (C) determination in the plasma of an adult patient
receiving 4 χ 200 mg of carbamazepine per day. The sample was
drawn 3.5 hours after the morning dose. Abscissa: time t (min).
Ordinate: Absorbance A. Column: 2 χ 2000 mm, stainless steel.
Stationary phase: /-octane/ethanol/water (volumes 85.7 1-f 14.01
4- 0.31). Flow rate: O.4 ml/min. Inlet pressure: 14 at. UV detector:
0.02 absorbance, full scale. Sample: 36.5 ng carbamazepine, correspond-
ing to a plasma level of 7.3 mg/1
'' V
Accuracy
Serum not containing carbamazepine gave no peak at
the corresponding retention volume. Carbamazepine
standards gave identical results whether extracted from
serum or directly dissolved in ethanol. Sufficient
separation of carbamazepine and its metabolites in the
serum of patients under continuous therapy was proved
by identification of the solute passing the detector
during the carbamazepine peak. Identification was
performed by UV-spectroscopy and thin layer chro-
matography according to a modified method of
CHRISTIANSEN (8).
For a preHminary evaluation of pharmacokinetic
constants of carbamazepine, the serum concentrations
were determined in two healthy persons (two authors
of this report) receiving a single oral dose of the drug.
The experimental results fitted rather well with the
data calculated by BATEMAN-functions (16) (Fig. 2).
Peak serum levels occurred at six to seven hours after

















Serum concentration profiles and tentatively calculated BATEMAN-
functions (dotted lines) in two healthy persons receiving a single dose
of carbamazepine. Abscissa: time t (h). Ordinate: serum concentration
c(mg/l). — Subject A: 10.7 mg/kg carbamazepine, BATEMAN-function:
c=9 .6 (e-°-018t_ e-0·»«*), t,/z:38 h. — Subject B: 10.9 mg/kgcarbamazepine. BAtEMAN-f unction: c = 11.6 (e-°-037t — e-°-14et),
tx/a:18.5h
38 h were observed. According to CEREGHINO et al. (17)
who recently reviewed papers reporting pharmaco-
kinetic studies of carbamazepine, biological h lflives
following cessation of therapy range from 14 to 72 h.
A major disadvantage of the method presented here
may be the fact that only carbamazepine can be assayed
in the same Chromatographie run. In liquid-solid
chromatography there is a pronounced compound
type selectivity. Drugs with different functional groups
generally show greatly differing retention volumes.
Often they cannot be determined under identical
Chromatographie conditions without special pro-
gramming or unacceptable loss of sensitivity. The
determination of different serum components by
liquid-solid chromatography generally requires the
injection of discrete aliquots of the same serum sample
under different Chromatographie conditions. Most
conveniently only solvent systems are changed, while
packing materials are kept unaltered. In our laboratory
diphenylhydantoin (18) and carbamazepine serum
concentrations are successively determined on the same
Perisorb A column.
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